• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-K filed by Aclarion Inc.

    3/31/25 4:30:26 PM ET
    $ACON
    Medical Specialities
    Health Care
    Get the next $ACON alert in real time by email
    NT 10-K 1 aclarion_ext.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON D.C. 20549

     

    FORM 12b-25

    NOTIFICATION OF LATE FILING

     

     

    (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K        
      ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR    

     

    For Period Ended: December 31, 2024

     

    ☐ Transition Report on Form 10-K

    ☐ Transition Report on Form 20-F

    ☐ Transition Report on Form 11-K

    ☐ Transition Report on Form 10-Q

     

    For the Transition Period Ended: _______________________________________

     

    Read Instruction (on back page) Before Preparing Form. Please Print or Type.

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     

     

    PART I - REGISTRANT INFORMATION

     

    Aclarion, Inc.


    Full Name of Registrant

     

     


    Former Name if Applicable

     

    8181 Arista Place, Suite 100


    Address of Principal Executive Office (Street and Number)

     

    Broomfield, CO 80021


    City, State, Zip Code

     

     

     

       

     

     

    PART II - RULES 12b-25 (b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

      (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
         
    ☒ (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject ☐ quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
         
      (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III - NARRATIVE

     

    Aclarion, Inc. (the “Company”) is unable to file its annual report on Form 10-K for the year ended December 31, 2024 within the prescribed time period without unreasonable effort and expense. We are requesting more time to compile the necessary information for the preparation of the 10-K report, and to allow more time for our independent registered public accounting firm to review our financial statements.

     

    The Company believes it will be able to file the annual report on or before the fifteenth calendar day following the prescribed due date.

     

     

    PART IV - OTHER INFORMATION

     

    (1) Name and telephone number of person to contact in regard to this notification:

     

    John Lorbiecki

     

    833

      275-2266
    (Name)   (Area Code)   (Telephone No.)

     

    (2) Have all other periodic reports required under section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).
      ☒ Yes ☐ No
       
    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
      ☐ Yes ☒ No

     

    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

    _______________________________________________________________________________________

     

     2 

     

     

    Aclarion, Inc.


    (Name of Registrant as Specified in Charter)

     

    has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

     

     

    Date: March 31, 2025 By:

    /s/ John Lorbiecki

      Name: John Lorbiecki
      Title: Chief Financial Officer

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     3 

     

    Get the next $ACON alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACON

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ACON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Thramann Jeffrey John

      4 - Aclarion, Inc. (0001635077) (Issuer)

      3/28/23 8:30:04 PM ET
      $ACON
      Medical Specialities
      Health Care
    • SEC Form 4: Thramann Jeffrey John bought $1,000 worth of Series A Preferred Stock (1 units at $1,000.00)

      4 - Aclarion, Inc. (0001635077) (Issuer)

      2/21/23 4:02:40 PM ET
      $ACON
      Medical Specialities
      Health Care
    • SEC Form 4: Ness Brent bought $9,769 worth of shares (18,500 units at $0.53), increasing direct ownership by 1,850% to 19,500 units

      4 - Aclarion, Inc. (0001635077) (Issuer)

      12/29/22 7:57:11 PM ET
      $ACON
      Medical Specialities
      Health Care

    $ACON
    Leadership Updates

    Live Leadership Updates

    See more
    • Aclarion Launches Second Clinical Utility and Economic (CLUE) Trial Site With First Surgeon in New Jersey

      CLUE is a Multi-center Trial to Identify how Often Nociscan's AI Data Changes the Initial Treatment Plan for Patients With Chronic Low Back Pain Dr. Justin Kubeck Will Initiate CLUE in New Jersey at Ocean Pain and Spine in Toms River BROOMFIELD, CO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today the expansion of the multi-center CLUE Trial to New Jersey. Justin Kubeck, MD, orthopedic spine surgeon and founder of Ocean Pain and Spine in Toms

      8/29/24 6:57:00 AM ET
      $ACON
      Medical Specialities
      Health Care
    • Aclarion Appoints Nicholas Theodore, MD as Principal Investigator for CLARITY Post-Market Trial Evaluating Nociscan in the Diagnosis and Treatment of Chronic Low Back Pain

      Nicholas Theodore, MD, FACS, FAANS, is Director of Neurosurgical Spine Center, Johns Hopkins, and Professor of Neurosurgery, Orthopaedics and Biomedical Engineering CLARITY is a Post-market, Multi-site Trial That Will Further Evaluate the Role of Nociscan in the Diagnosis and Surgical Ttreatment of Chronic Low Back Pain. CLARITY is Targeted to Begin in the Second Half of 2023. BROOMFIELD, CO, May 02, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pa

      5/2/23 7:00:00 AM ET
      $ACON
      Medical Specialities
      Health Care
    • Aclarion Appoints George Frey MD as Seventh Key Opinion Leader Surgeon Advisor

      Broomfield, CO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that George Frey MD, Founder of the Colorado Comprehensive Spine Institute, will advise the company as a key opinion leader (KOL). Dr. Frey is a renowned surgeon and inventor with dozens of US and worldwide patents in medical devices, technologies, and methods. Dr. Frey's experiences as a clinician and entrepreneur will provide valuable direction to Aclarion.

      1/17/23 8:29:31 AM ET
      $ACON
      Medical Specialities
      Health Care

    $ACON
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site

      USC Spine Center, part of Keck Medicine of USC, specializes in treating complex spine conditions with the latest cutting-edge technologiesCLARITY is a randomized clinical trial designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 20, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location

      5/20/25 6:00:00 AM ET
      $ACON
      Medical Specialities
      Health Care
    • Aclarion Announces Texas Back Institute as New CLARITY Trial Site

      Texas Back Institute is a world leader in advancing spine technology, science, and education, as well as patient careCLARITY is a randomized clinical trial designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 12, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back

      5/12/25 7:34:07 AM ET
      $ACON
      Medical Specialities
      Health Care
    • Aclarion Welcomes Advocate Health as CLARITY Trial Site

      Advocate Health actively participates in research studies and is an innovator in technology, including spine The CLARITY trial is designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 05, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the

      5/5/25 6:00:00 AM ET
      $ACON
      Medical Specialities
      Health Care

    $ACON
    SEC Filings

    See more
    • SEC Form 10-Q filed by Aclarion Inc.

      10-Q - Aclarion, Inc. (0001635077) (Filer)

      5/15/25 7:54:10 AM ET
      $ACON
      Medical Specialities
      Health Care
    • SEC Form DEF 14A filed by Aclarion Inc.

      DEF 14A - Aclarion, Inc. (0001635077) (Filer)

      5/12/25 8:27:41 PM ET
      $ACON
      Medical Specialities
      Health Care
    • SEC Form EFFECT filed by Aclarion Inc.

      EFFECT - Aclarion, Inc. (0001635077) (Filer)

      5/6/25 12:15:15 AM ET
      $ACON
      Medical Specialities
      Health Care

    $ACON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Aclarion Inc.

      SC 13G/A - Aclarion, Inc. (0001635077) (Subject)

      11/13/24 3:06:29 PM ET
      $ACON
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Aclarion Inc.

      SC 13G - Aclarion, Inc. (0001635077) (Subject)

      9/5/24 4:19:39 PM ET
      $ACON
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Aclarion Inc. (Amendment)

      SC 13G/A - Aclarion, Inc. (0001635077) (Subject)

      3/29/24 5:00:57 PM ET
      $ACON
      Medical Specialities
      Health Care